Moleculin Biotech, Inc. (MBRX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$8.24

From 52W high−96.59%

Volume13778.00

Market cap$8.84M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$8.24

From 52W high

−96.59%

Volume

13778.00

Market cap

$8.84M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

48.1

MomentumView details →

1D Return

+1.93%

YTD Return

−87.17%

SummaryUpdated Jun 1, 2026

Moleculin Biotech, Inc. (NASDAQ:MBRX) is a clinical-stage pharmaceutical company founded in 2015 and headquartered in Houston, Texas. The company went public in June 2016 and focuses on developing innovative drug candidates specifically designed to treat highly resistant tumors and viruses. Moleculin operates in the biotechnology sector within the broader healthcare industry, positioning itself as a specialized developer of oncology therapeutics with a particular emphasis on addressing unmet medical needs in cancer treatment where existing therapies have failed or proven inadequate.

Ask drillr about Moleculin Biotech, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−261.73%

ROA (TTM)

−143.82%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+1.28%

FCF YoY

−18.81%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+84.97%

EBITDA YoY

−31.51%

MomentumView details →

1D Return

+1.93%

YTD Return

−87.17%

1Y Return

−96.44%

RSI (14)

48.1

vs 50D SMA

−20.00%

vs 200D SMA

−78.35%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

0.94x

Quick Ratio

0.94x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.40

EPS Surprise

9.68%

Beats (12Q)

8/12

Next Q EPS Est

−$8.53

Avg Surprise (4Q)

32.88%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−30.33M

Op. CF (TTM)

−25.36M

Next earningsNov 12, 2026 →

Latest newsMore news →

Moleculin Biotech filed an amendment to its certificate of incorporation to effect a 1-for-20 reverse stock split of its common stock.19d ago

Moleculin Biotech elected Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco and Elizabeth A. Cermak as directors.26d ago

Similar companies

MetaVia Inc.MTVA Actuate Therapeutics IncACTU Lantern Pharma Inc.LTRN GT Biopharma, Inc.GTBP Chemomab Therapeutics Ltd.CMMB COSCIENS Biopharma Inc.CSCI Find similar companies →

Latest newsMore news →

Moleculin Biotech filed an amendment to its certificate of incorporation to effect a 1-for-20 reverse stock split of its common stock.19d ago Moleculin Biotech elected Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco and Elizabeth A. Cermak as directors.26d ago